ストックスクリーナーアプリを入手
0.8199
8.90%
-0.0801
Tiziana Life Sciences Ltd (TLSA) 最新ニュース
Stoke Therapeutics (NASDAQ:STOK) and Tiziana Life Sciences (NASDAQ:TLSA) Head to Head Survey - Defense World
Tiziana Life Sciences Announces Agreement With Renaissance Lakewood -February 21, 2025 at 10:50 am EST - Marketscreener.com
Tiziana Life Sciences & Renaissance Partner on Nasal Foralumab Production - Contract Pharma
Tiziana Life Sciences Teams Up With Renaissance Lakewood on Nasal Drug Delivery - Marketscreener.com
Tiziana Life Sciences advances foralumab towards commercialization with key manufacturing partnership - Proactive Investors UK
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC - The Manila Times
Tiziana Life Sciences Partners with Renaissance Lakewood to Advance Development of Intranasal Foralumab for Neurodegenerative Diseases - Nasdaq
Tiziana Life Sciences announces dosing of additional patients in MS Expanded Access Program - Proactive Investors UK
Breakthrough MS Treatment Shows Promise: 100% Patient Response Rate in Expanded Trial - StockTitan
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Expands By 128.0% - MarketBeat
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease - GlobeNewswire
Tiziana Life Sciences says foralumab shows promise in Alzheimer’s treatment - Proactive Investors USA
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Drop in Short Interest - MarketBeat
Tiziana Life Sciences Faces Nasdaq Compliance Challenge - MSN
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update - MarketBeat
Tiziana Life Sciences (NASDAQ:TLSA) Stock Quotes, Forecast and News Summary - Benzinga
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Drops By 21.4% - Defense World
Tiziana Life Sciences (FRA:0RP) Total Liabilities : €8.46 Mil (As of Jun. 2024) - GuruFocus.com
Tiziana reports progress in spinal cord injury treatment - MSN
Tiziana Life Sciences Ltd (NASDAQ: TLSA) Jumps 11.06%: What Could Be On The Way Going Forward? - Stocks Register
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 - The Manila Times
Tiziana reports progress in spinal cord injury treatment By Investing.com - Investing.com Australia
Tiziana Life Sciences reports promising preclinical results for nasal anti-CD3 in spinal cord injury - Proactive financial news
Tiziana's Nasal Treatment Shows Promise for Spinal Cord Injury Recovery in Breakthrough Study - StockTitan
Neurology-Focused Tiziana Life Confirms Discovery In Multiple Sclerosis Therapy Study - Benzinga
Tiziana Life Sciences not to engage in capital raising activities for the immediate future - The Manila Times
Tiziana Life Sciences Halts Capital Raising Plans After Promising MS Treatment Biomarker Discovery - StockTitan
Tiziana Life Sciences pauses capital raising activities - Proactive Investors USA
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab - The Manila Times
Tiziana Life Sciences identifies new immune biomarkers in MS patients treated with foralumab - Proactive Investors UK
Tiziana Life Sciences Reveals Breakthrough Biomarkers in Multiple Sclerosis Treatment Study - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short Interest - MarketBeat
3 Penny Stocks In US With Market Caps Below $300M - Simply Wall St
Tiziana Life Sciences’ foralumab reduces side effects of discontinuing GLP-1 agonists - Proactive financial news
Tiziana reports progress in immunotherapy treatment - Investing.com India
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 - The Manila Times
Tiziana's Breakthrough Nasal Therapy Enhances GLP-1 Drug Benefits, Reduces Side Effects - StockTitan
Tiziana’s foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Nigeria
Tiziana's foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Canada
Tiziana Life Sciences welcomes publication of article highlighting foralumab’s potential in neurological diseases - Proactive Investors UK
Tiziana's foralumab shows promise in neurodegenerative diseases - Investing.com India
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease - The Manila Times
Tiziana's Foralumab Shows Breakthrough Potential for Multiple Sclerosis in Nature Reviews Study - StockTitan
US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus - Benzinga
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Decline in Short Interest - MarketBeat
Now Is The Time To Build A Position In Tiziana Life Sciences Ltd (NASDAQ:TLSA) - Marketing Sentinel
Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis - Seeking Alpha
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors Australia
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):